Edwards Lifesciences (EW) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last few weeks:

• 10/31/2026 – Edwards Lifesciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/27/2026 – Edwards Lifesciences was given a new $104.00 price target by Deutsche Bank Aktiengesellschaft.
• 10/27/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by TD Cowen.
• 10/23/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Evercore.
• 10/17/2026 – Edwards Lifesciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/15/2026 – Edwards Lifesciences had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Edwards Lifesciences had its price target lowered by Robert W. Baird from $94.00 to $90.00. They now have a “neutral” rating on the stock.
• 10/8/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by UBS Group. They now have a $110.00 price target on the stock, up from $90.00.
• 10/7/2026 – Edwards Lifesciences was upgraded by Barclays to “strong-buy”.
• 10/6/2026 – Edwards Lifesciences is now covered by Barclays. They set an “overweight” rating and a $110.00 price target on the stock.
• 10/5/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by Citigroup. They now have a $101.00 price target on the stock, up from $96.00.
• 10/5/2026 – Edwards Lifesciences had its price target raised by Evercore from $100.00 to $102.00. They now have an “outperform” rating on the stock.
• 10/2/2026 – Edwards Lifesciences had its price target raised by JPMorgan Chase & Co. from $100.00 to $105.00. They now have an “overweight” rating on the stock.
• 9/26/2026 – Edwards Lifesciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/12/2026 – Edwards Lifesciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/11/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by BTIG Research. They now have a $110.00 price target on the stock.

Edwards Lifesciences Price Performance

NYSE:EW traded up $2.46 during trading hours on Tuesday, reaching $95.72. The stock had a trading volume of 3,124,707 shares, compared to its average volume of 4,477,308. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a 52 week low of $74.66 and a 52 week high of $96.29. The company has a 50 day moving average price of $88.22 and a two-hundred day moving average price of $85.47. The stock has a market capitalization of $55.12 billion, a PE ratio of 55.01, a PEG ratio of 2.40 and a beta of 0.87.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.